wydrukuj poleć znajomym zamów materiały
Od ilu lat pracuje Pani/Pan na różnych stanowiskach menedżerskich:

powyżej 20 lat
powyżej 15 lat
powyżej 10 lat
powyżej 5 lat
poniżej 5 lat
jeszcze nie byłam/-em menedżerem
nie chcę być menedżerem


Subskrypcja najnowszych ofert pracy





Nasi partnerzy:

rp.pl
gazeta.pl
onet.pl
interia.pl
wp.pl

Changing Landscape of Prostate Cancer Research and Development 2017.06.10

New York City, USA - June 06, 2017 - Prostate cancer remains a cancer that affects large numbers of patients. It remains a tumor that has not been completely solved and the biology is just being fully understood. With all our scientists working hard to make a difference, there are numerous promising opportunities to provide new types of therapeutics that will change the course of this disease.

Photo courtesy of Marco Gottardis
 

New York City, USA – June 06, 2017 

25 Years of Prostate Cancer Treatments - Some Thoughts from ASCO



By Marco Gottardis,
Janssen Oncology, Prostate Cancer DAS Leader

As I attend my 19th ASCO annual meeting this year, I take a minute to pause and think about how treatments in various cancers have evolved in the past few decades.

Some approaches have stumbled, while others have raced forward showing great promise and changing positively the lives of thousands of cancer patients.
I have seen great strides overall in cancer where individuals with cancer can continue to live active, fulfilling lives.

As the head of the Prostate Cancer Disease Area Stronghold at Janssen Oncology, I have the amazing opportunity to work alongside brilliant and passionate scientists in this area.
I get a ringside seat on the enormous changes taking place in this disease.

In all things research, finding answers for the treatment of prostate cancer has been a slow and arduous process.

When I first started my career in cancer research, 25 plus years ago, there was little available for prostate cancer; it was a virtual desert.

Surgical castration, for which Charles Huggins received his Nobel prize >50 years ago to cut off the flow of testosterone that fuels the prostate cancer, was the only real treatment.

While surgery was not a welcomed alternative, it was an option. It provided hope and time, albeit mostly short-lived, in outcomes for metastatic prostate cancer patients.

In the late 1970’s, there was the emergence of luteinizing-hormone-releasing hormone (LHRH) agonists.

Sadly, despite the positive side of not needing castration surgery, this approach gave similar outcomes.

There was no benefit to overall survival and after that treatment ran its course and was no longer effective, there was no plan B.

Since then, it is clear that the landscape of prostate cancer has changed by the expanding approval of new agents with new or improved mechanisms of action.

Research has driven approaches that include the ability to inhibit synthesis of androgens and androgen receptor (AR) antagonists that more effectively directly block AR–a major break-through for those in the advanced stages of the disease.

These new agents, for the first time, show evidence of an increase in overall survival in prostate cancer patients.
We’ve moved forward, but for men facing prostate cancer, not enough.

We continue to need treatments that can directly prevent the growth of prostate cancer, and we need options for treatment without the ill effects of testosterone deprivation.
We also need answers for earlier stages of disease, and in prevention to stop the cancer from developing in the first place.


Marco Gottardis
Photo courtesy of LinkedIn
 
In my opinion, for that to happen, we need to work on the following strategies:

One, provide another alternative for patients who have failed all hormonal therapies.

These treatments will include third-generation AR agents, that can block the androgen receptor through other mechanisms than just blocking at the androgen binding site or androgen synthesis.


Two, develop greater understanding of prostate cancer molecular phenotypes to enable personalized targeted treatment regimens.

As our molecular understanding of prostate cancer grows, so does our ability to identify gene defects and mutations to enable selection of personalized targeted therapies for patients. One such example is the class of drugs referred to as poly ADP ribose polymerase (PARP) inhibitors, which prevent cancer cells from repairing their DNA and eventually causing them to die.
It’s a new mechanism for treating prostate cancer, appropriate for certain patients, with DNA repair defects.
A subgroup of 20-25 percent of prostate cancer patients have DNA defects which in the future will be identified by a simple blood test. Initial clinical data suggests that prospective selection of patients with DNA repair defects can predict response to PARP inhibitors.


Three, treat patients earlier, to see if we can provide more durable responses in  earlier stages of the disease  and to drive cures.

A new generation of treatments that include vaccines, targeted therapy, immune-therapy and AR inhibitors may have the opportunity to become the anchor therapies for these earlier stage patients.


If I think about the progress being made for prostate cancer treatment, I am pleased to say now, some two decades later that the sand is shrinking and our hopes are becoming less distant mirages.

Prostate cancer remains a cancer that affects large numbers of patients.
It remains a tumor that has not been completely solved and the biology is just being fully understood.

With all our scientists working hard to make a difference, there are numerous promising opportunities to provide new types of therapeutics that will change the course of this disease.


Marco Gottardis

Vice President Oncology Disease Area Stronghold Leader

Vice President at Janssen, Pharmaceutical Companies of Johnson and Johnson


https://www.linkedin.com/in/marco-gottardis-39361861  


Source: LinkedIn Pulse

https://www.linkedin.com/pulse  


Prostate cancer remains a cancer that affects large numbers of patients.

Please see  Mesothelioma.net  for more information on mesothelioma cancer:

https://mesothelioma.net  

Please see  https://mesothelioma.net/mesothelioma  for more specific information on mesothelioma cancer.



ASTROMAN Magazine - 2017.06.09

Siemens Healthineers Debuts Symbia Intevo Bold SPECT/CT

https://www.astroman.com.pl/index.php?mod=magazine&a=read&id=2273  


ASTROMAN Magazine - 2017.05.27

Reid Hoffman: My New Investment in Change.org, The Global Hub For Positive Social Impact

https://www.astroman.com.pl/index.php?mod=magazine&a=read&id=2260  


ASTROMAN Magazine - 2017.04.21

Apple celebrates Earth Day with new initiatives and stories of innovation

https://www.astroman.com.pl/index.php?mod=magazine&a=read&id=2233  


ASTROMAN Magazine - 2017.04.19

Shelly Palmer: Can Self-Driving Cars Ever Really Be Safe?

https://www.astroman.com.pl/index.php?mod=magazine&a=read&id=2232  


ASTROMAN Magazine - 2017.04.14

Jamie Dimon, Chairman & CEO of JPMorgan Chase: Good Reputation Advances Your Career

https://www.astroman.com.pl/index.php?mod=magazine&a=read&id=2229  


ASTROMAN Magazine - 2017.03.13

William D. Cohan: It's time we stop hating Wall Street and start appreciating what it does for the U.S. economy

https://www.astroman.com.pl/index.php?mod=magazine&a=read&id=2210  


ASTROMAN Magazine - 2017.03.01

The new Hanoi Lotus Centre project has been featured on Archdaily!


https://www.astroman.com.pl/index.php?mod=magazine&a=read&id=2201  


ASTROMAN Magazine - 2017.01.31

How Facebook Uses Data Analytics To Understand Your Posts And Recognize Your Face

https://www.astroman.com.pl/index.php?mod=magazine&a=read&id=2186  


ASTROMAN Magazine - 2017.01.13

JPMorgan Chase and CCSSO Announce USD 20 Million to Improve Career Education for Young People in 10 U.S. States

https://www.astroman.com.pl/index.php?mod=magazine&a=read&id=2228  


ASTROMAN Magazine - 2016.06.25

Toyota launches Biodiversity & Sustainability Learning Center to complement its Biotope project in Thailand

https://www.astroman.com.pl/index.php?mod=magazine&a=read&id=2081  



Editor-in-Chief of ASTROMAN magazine: Roman Wojtala, Ph.D.


wydrukuj ten artykuł
  strona: 1 z 1
polecamy artykuły
Make Way for Holograms: New Mixed Reality Technology Meets Car Design As Ford Tests Microsoft HoloLens Globally
Renault, Nissan and Mitsubishi Motors Alliance 2022: New plan targets annual synergies of EUR10 billion and forecasts unit sales of 14 million and combined revenues of USD240 billion
Tesla: Supercharging Cities
Highlights from Apple's keynote event. The future is here: iPhone X
deepsense.ai's research on robotics at prestigious 1st Annual Conference on Robot Learning
Ohio's Fintech71 Accelerator Picks 10 Startups for Its Inaugural Cohort
The International Exhibition EXPO 2017 Astana. Złoty medal dla polskiego pawilonu w Kazachstanie
Musical "Karol" - spektakl o życiu świętego Jana Pawła II po premierze w Krakowie, wystawiony zostanie w Łodzi i Gdańsku
The new Nissan LEAF - embodying Nissan Intelligent Mobility
Chris Westphal Joins Data Analytics Innovator DataWalk as Chief Analytics Officer
Barry Callebaut to acquire Ingredients Division of Gertrude Hawk Chocolates
Barry Callebaut reveals the fourth type in chocolate: Ruby
The new Neptune. Data scientists on a cloud with the new Machine Learning Lab from deepsense.ai
Prof. Leszek Jesień z PSE został członkiem Rady Nadzorczej TSCNET Services GmbH
DowDuPont Merger Successfully Completed. Global Leaders in Agriculture, Materials Science and Specialty Products
strona główna  |  oferty pracy  |  executive search  |  ochrona prywatności  |  warunki używania  |  kontakt     RSS feed subskrypcja RSS
Copyright ASTROMAN © 1995-2017. Wszelkie prawa zastrzeżone.
Projekt i wykonanie: TAU CETI.